After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
We are very excited to launch our new website! Please take a few moments to click around and explore...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...